Drug intelligence / Profile preview

chlorpheniramine + phenylephrine + methscopolamine

Development stage
Unknown
Lead developer
Breckenridge Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This is an **oral combination drug** used for the temporary relief of symptoms caused by allergies, hay fever, or the common cold, such as runny/stuffy nose, sneezing, itchy/watery eyes, sinus congestion, and throat irritation[1][2][3][5][6][7]. It contains three components: - **Chlorpheniramine** is a first-generation antihistamine acting as a histamine H1 receptor antagonist, decreasing allergic symptoms[2][3][9]. - **Phenylephrine** is a sympathomimetic decongestant acting as an alpha-1 adrenergic receptor agonist, reducing nasal congestion[6]. - **Methscopolamine** is an anticholinergic that reduces secretions (such as nasal, bronchial, and GI), additionally decreasing gastric acid[7]. Primary indications are symptomatic relief for upper respiratory tract symptoms caused by allergies or colds. It does not treat infection or underlying causes and is used as supportive symptomatic therapy.

Brand names
Dura-Vent DAEX-Histine SyrupExtendrylExtendryl Jr.Extendryl Sr.Extendryl SyrupDallergyDallergy CapletsDallergy SyrupChewableTriallRelcof PEResconSympak PDXOmnihist LA
Other names
chlorpheniramine + phenylephrine + methscopolamine
02

Targets

ADRA1A (α1A)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on chlorpheniramine + phenylephrine + methscopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorpheniramine + phenylephrine + methscopolamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call